RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1200
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1185 to $1200.
June 04, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals and raises the price target from $1185 to $1200.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively influence investor sentiment and drive short-term price appreciation for Regeneron Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100